This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Breast Cancer
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. Riluzole may help slow the growth of tumor cells. PURPOSE: This phase I trial is studying riluzole in women with stage I, stage II, or stage IIIA breast cancer.

Provided treatments

  • Drug: riluzole
  • Genetic: polymorphism analysis
  • Procedure: axillary lymph node biopsy
  • Procedure: digital image analysis
  • Procedure: needle biopsy
  • Procedure: sentinel lymph node biopsy
  • Procedure: therapeutic conventional surgery
Tris trial is registered with FDA with number: NCT00903214. The sponsor of the trial is Barbara Ann Karmanos Cancer Institute and it is looking for 0 volunteers for the current phase.
Official trial title:
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment